866-997-4948(US-Canada Toll Free)

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

Published By :

DelveInsight

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 311 Pages

DelveInsights, PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.
This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
Scope
The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
The report provides the marketed drugs information including its sales, development activities and details of patent expiry
The report provides the insight of current and future market for PD and PD-L1 inhibitors
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
The report also gives the information of dormant pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy
Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Introduction
Executive Summary
Programmed Death 1 (PD-1)
Programmed Death Ligand 1 (PD-L1)
Role of PD-1 and PD-L1 pathways
MOA of PD-1 and PD-L1 inhibitors
Significance of PD-1 and PD-L1 inhibitors
PD-1 and PD-L1 Active Therapy Areas & Epidemiology
Metastatic Renal Cell Carcinoma
Squamous Cell Carcinomas of the Head and Neck
Metastatic Colorectal Cancer
Non-Small Cell lung cancer
Biomarkers - PD-1 and PD-L1 inhibitors
Market Overview
Comparative Analysis of Pipeline &Marketed Drugs
Marketed Product of PD-1 and PD-L1 drugs Overview
Marketed Drug Candidate Profiles
Pembrolizumab
Nivolumab
Atezolizumab
Marketed Drugs Sales
Details of Patent Expiry of Marketed Drugs
Current and Future Market for PD and PD-L1 inhibitors
Challenges and Barriers associated with use of PD and PD-L1 inhibitors
PD-1/PD-L1Combinations Creating Boom
Pipeline Therapeutics
An overview of pipeline products
Pipeline Therapeutics Overview
Therapeutics under Development by MOA
Therapeutics under Development by Companies
Last Stage Products (Phase III and Filed)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Unknown Stages Molecules
Therapeutic Assessment of pipeline
Therapeutics under Development by Product Type
Therapeutics under Development by Phase for Monotherapy
Therapeutics under Development by Phase for Combination therapy
Therapeutics under Development by Molecule Type
Assessment by Stage and Molecule Type
Therapeutics under Development by Route of Administration
Assessment by Stage and Route of Administration
Dormant Products
Comparative Analysis
SWOT Analysis
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

List of Table

Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017
Table 2: PD-1 Marketed Drugs, 2017
Table 3: Sales of Marketed drugs, 2017
Table 4: Details of patent expiry of marketed molecules, 2017
Table 5: Mercks drug- Keytruda (Pembrolizumab) Partners for Combination Therapies
Table 6:Bristol Myers Squibbs drug-Opdivo (nivolumab) Partners for Combination Therapies
Table 7: Roches drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies
Table 8: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2017
Table 9: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Last Stage Products (Phase III and Filed),2017
Table 12: Mid Stage Products (Phase II), 2017
Table 13: Early Stage Products (Phase I and IND), 2017
Table 14: Pre-Clinical and Discovery Products, 2017
Table 15: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017
Table 16: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017
Table 17:Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017
Table 18: Number of Products under Development by Molecule Type, 2017
Table 19: Assessment by Stage and Molecule Type, 2017
Table 20:Number of Products under Development by Route of Administration, 2017
Table 21:Assessment by Stage and Route Of Administration, 2017
Table 22: Dormant Products, 2017

List of Chart

Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017
Figure 2: Sales of marketed drugs, 2017
Figure 3: Details of patent expiry of marketed molecules, 2017
Figure 4: Number of Products under Development forPD-1 and PD-L1 inhibitors Drugs, 2017
Figure 5: Comparative Graph forPD-1 and PD-L1 inhibitors Drugs, 2017
Figure 6:Last Stage Products (Phase III), 2017
Figure 7: Mid Stage Products (Phase II), 2017
Figure 8: Early Stage Products (Phase I and IND), 2017
Figure 9:Pre-Clinical and Discovery Products, 2017
Figure 10: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2017
Figure 11: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2017
Figure 12: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017
Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2017
Figure 14: Assessment by Stage and Molecule Type, 2017
Figure 15:Percentage of pipeline drugs by Route of Administration(%), 2017
Figure 16: Assessment by Stage and Route of Administration, 2017
Figure 17: Dormant Products, 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *